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Objective: To evaluate the additive intraocular pressure (IOP)-lowering efficacy and safety of 
fixed-combination brimonidine 0.2%/timolol 0.5% compared with timolol 0.5% at peak and 
trough effect when used as therapy adjunctive to latanoprost 0.005% in patients with glaucoma 
or ocular hypertension who require additional IOP lowering.
Methods: In this prospective, randomized, multicenter, investigator-masked, parallel-group 
study, patients were treated with latanoprost monotherapy for at least four weeks prior to baseline. 
At baseline on latanoprost, patients with IOP $21 mmHg in at least one eye were randomized 
to twice-daily fixed brimonidine-timolol (n = 102) or timolol (n = 102), each adjunctive to 
latanoprost for 12 weeks. IOP was measured at 8 am and 10 am at baseline, week 6, and week 
12 and evaluated in the per protocol population. The primary efficacy endpoint was peak IOP 
lowering at 10 am, week 12. Safety measures included adverse events.
Results: Baseline mean IOP was similar at 10 am in the treatment groups (brimonidine-timolol 
23.4 mmHg; timolol 23.0 mmHg). The mean additional reduction from latanoprost-treated 
baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) 
with timolol at 10 am, week 12 (P , 0.001). Patients treated with fixed brimonidine-timolol 
adjunctive to latanoprost were significantly more likely than patients treated with adjunctive 
timolol to achieve an IOP ,18 mmHg (P = 0.028) and a $20% reduction in IOP from baseline 
(P = 0.047) at both 8 am and 10 am in week 12. Adverse events occurred in 14.7% of fixed 
brimonidine-timolol patients and 12.7% of timolol patients. Biomicroscopy findings were similar 
between the treatment groups after 12 weeks of treatment.
Conclusion: Fixed-combination brimonidine-timolol reduced IOP significantly more effec-
tively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma 
and ocular hypertension. Both fixed brimonidine-timolol and timolol were well tolerated as 
agents adjunctive to latanoprost.
Keywords: brimonidine, drug combinations, glaucoma, intraocular pressure, ocular hyperten-
sion, timolol
Introduction
Patients with glaucoma and ocular hypertension frequently require multiple intraocular 
pressure (IOP)-lowering medications. The topical once-daily prostaglandin analogs 
(latanoprost, bimatoprost, and travoprost) are the most commonly prescribed primary 
IOP-lowering therapy based on their safety and efficacy profile. However, some patients 
are unable to either achieve or maintain their target IOP with monotherapy alone. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In the Ocular Hypertension Treatment Study, for example, 
40% of treated patients required two or more medications 
to achieve a 20% reduction from baseline IOP by year 5.1 In 
a study by Covert and Robin,2 over 20% of patients treated 
with a once-daily prostaglandin analog added another 
IOP-lowering medication to their regimen within a year of 
initiating treatment.
The fixed combination of brimonidine 0.2%/timolol 0.5% 
has been demonstrated to reduce IOP more effectively than 
either brimonidine 0.2% or timolol 0.5% used alone and to 
be better tolerated than brimonidine 0.2% monotherapy.3 
A fixed combination of brimonidine-timolol has also been 
shown to be as efficacious and well tolerated as concomitant 
use of separate bottles of brimonidine 0.2% and timolol 
0.5%.4 When multiple drug therapy is needed, use of a fixed 
combination of two IOP-lowering medications in one bottle 
may be preferred to simplify the medication regimen and 
enhance patient convenience and adherence to treatment.5 
Studies have suggested that adherence with topical medica-
tions may be reduced with the addition of each adjunctive 
glaucoma agent.6,7
The efficacy and safety of fixed brimonidine-timolol 
used as therapy adjunctive to prostaglandin analogs has 
been evaluated previously in open-label studies8,9 and in a 
comparison study of a fixed combination of dorzolamide and 
timolol.10 The purpose of the present study was to evaluate 
the additive IOP-lowering efficacy and safety of fixed-
combination brimonidine-timolol compared with timolol 
alone at 8 am (trough effect) and 10 am (peak effect) when 
each is used as therapy adjunctive to latanoprost in patients 
requiring additional IOP lowering.
Methods
This prospective, randomized, multicenter (15 sites in the 
US and Canada), investigator-masked, parallel-group clinical 
study compared fixed brimonidine-timolol with timolol as 
adjunctive therapy for patients on latanoprost who required 
additional IOP lowering. The study was approved by the 
institutional review board at each site. All patients who 
participated in the study provided written informed consent. 
The study is registered at clinicaltrials.gov with the identifier 
NCT00735449.
Adult patients with a diagnosis of ocular hypertension or 
primary open-angle glaucoma, chronic angle-closure glau-
coma with patent iridotomy or iridectomy, pseudoexfoliative 
glaucoma, or pigmentary glaucoma requiring treatment with 
IOP-lowering medication who had inadequate IOP control 
after at least four continuous weeks of latanoprost 0.5% 
(Xalatan®; Pfizer Inc, New York, NY) monotherapy were 
enrolled in the study. Patients were required to have IOP 
$21 mmHg and ,34 mmHg in at least one eligible eye (the 
study eye) at both 8 am and 10 am on latanoprost-treated 
baseline. Patients were also required to have best-corrected 
visual acuity equivalent to a Snellen score of 20/100 or 
better in both eyes. Primary exclusion criteria included 
uncontrolled systemic disease or active ocular disease other 
than glaucoma or ocular hypertension that in the judgment 
of the investigator would interfere with study interpretation, 
any corneal abnormality that would preclude accurate IOP 
readings, history of or active ocular infection/inflammation, 
visual field loss indicative of end-stage glaucoma, history of 
intraocular surgery or glaucoma laser surgery within three 
months prior to baseline, any history of refractive surgery, 
any contraindication to beta-blocker or brimonidine therapy, 
presence of severe cardiovascular disease, and pregnant, 
lactating, or potential for pregnancy.
All patients were treated bilaterally with latanoprost 
monotherapy once daily in the evening for at least four weeks 
prior to the baseline visit (day 0). Patients on IOP-lowering 
medications at screening underwent a four-week washout 
of all medications other than latanoprost prior to baseline; 
patients not on latanoprost at screening were run in on 
latanoprost for four weeks prior to baseline; and patients 
on latanoprost monotherapy at screening were continued on 
latanoprost monotherapy for 2–28 days until baseline. At the 
baseline visit, patients who met all eligibility criteria for the 
study continued on latanoprost and were randomly assigned 
with a 1:1 allocation to bilateral adjunctive treatment with 
twice-daily brimonidine tartrate 0.2%/timolol maleate 0.5% 
ophthalmic solution (Combigan®; Allergan Inc, Irvine, CA) 
or timolol maleate 0.5% ophthalmic solution for 12 weeks. 
The randomization code was computer-generated, and 
personnel responsible for collection of efficacy and safety 
measures were masked to treatment assignment. To maintain 
masking of the investigators, bottles of the study drugs were 
overlabeled and provided to patients in identically appear-
ing masked cartons labeled with the patient randomization 
number, and patients were instructed not to discuss their 
study medication with the investigator or office staff. An indi-
vidual at each site, not otherwise involved in the study, was 
assigned to dispense study medications and retrieve them 
from patients.
Patients were instructed to instill one drop of latanoprost 
in each eye once daily at 8 pm (±15 minutes) and to instill 
one drop of the study medication in each eye twice daily, 
in the morning at 8 am (±15 minutes) and in the evening at Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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five minutes after the instillation of latanoprost. Patients were 
scheduled for follow-up visits at weeks 6 and 12. At the week 
6 and week 12 study visits, the study medication was instilled 
by office personnel after the 8 am IOP measurement.
The primary efficacy endpoint was mean IOP at peak 
effect (10 am) at week 12. IOP was measured in both eyes 
using a Goldmann applanation tonometer at 8 am and 
10 am at baseline and at the week 6 and week 12 visits. Two 
consecutive measurements were taken for each eye, and the 
average value was used for analysis. For patients with both 
eyes eligible for the study, efficacy was evaluated in the worse 
eye (the eye with the higher IOP at baseline).
Safety outcome measures included adverse events and 
ocular signs on slit-lamp biomicroscopy. Biomicroscopic 
findings were graded on a scale of 0 = none, 0.5 = trace, 
1 = mild, 2 = moderate, and 3 = severe. An adverse event 
was defined as any untoward medical occurrence in a patient 
during the course of a study. At each follow-up visit, patients 
were asked whether any adverse events had occurred since 
the previous visit. All adverse events observed by the investi-
gator or reported by patients were recorded, and the investiga-
tor documented the severity of the adverse events and their 
potential relationship to study treatment. An adverse event 
was determined by the investigator to be treatment-related 
when there was a reasonable possibility of a causal relation-
ship between the study medication and the event.
The preplanned analyses of IOP were based on observed 
data from the per protocol patient population with no 
imputation for missing values. The per protocol population 
was defined as all patients who had efficacy evaluations at 
baseline and during follow-up, and who used no prohibited 
medications and had no prohibited procedures during the 
study that could interfere with the study objectives. The 
a priori statistical plan for the study included analyses 
of mean IOP, mean change from baseline IOP, and the 
percentage of patients with a decrease from baseline IOP 
of 20% or more. Baseline differences in IOP between 
treatment groups were analyzed with t-tests, and differ-
ences in IOP between treatment groups at follow-up were 
analyzed using analysis of covariance with baseline IOP 
as the covariate. Post hoc analysis of the percentage of 
patients with IOP less than 14, 15, 16, 17, and 18 mmHg 
at both the 8 am and 10 am time points at week 12 and 
the within-group changes in IOP from baseline were also 
performed. The Fisher’s Exact test was used to compare 
the percentages of patients between treatment groups. 
Within-group changes in IOP from baseline were analyzed 
using paired t-tests.
Summary statistics were calculated for demographic and 
safety parameters. All randomized patients received at least 
one dose of study medication and were included in the safety 
analyses. Statistical analyses were performed using JMP 
7.0 software (SAS Institute, Cary, NC). All statistical tests 
were two-tailed with the alpha level for significance set at 
0.05. A sample size calculation estimated that 72 patients in 
each group would provide 80% power to detect a 1.5 mmHg 
difference between groups in the primary outcome. The 
planned sample size of 100 patients in each treatment group 
was chosen to ensure 80% power in the primary analysis, 
assuming a dropout rate of 15% and additional exclusions of 
patients from the per protocol population used for analysis.
Results
Patient baseline characteristics  
and disposition
A total of 204 patients with inadequate IOP control on 
latanoprost alone were enrolled in the study and randomized 
to adjunctive treatment with fixed brimonidine-timolol or 
timolol. Patient demographics at baseline were comparable 
between groups (P $ 0.123) and are listed in Table 1. The 
mean age of patients was 64 years, and almost all of the 
patients (196/204, 96.1%) were using at least one IOP-
lowering medication at screening. Visual fields in the study 
eye were reported to be abnormal in the majority (63.6%) 
of patients.
Figure 1 illustrates patient flow through the study. The 
study was completed by 93.1% (95/102) of patients in the 
fixed-combination plus latanoprost group and 94.1% (96/102) 
of patients in the timolol plus latanoprost group. Reasons 
Table 1 Demographics and clinical characteristics of patients at 
baseline
Fixed 
brimonidine-timolol 
and latanoprost  
(n = 102)
Timolol and 
latanoprost 
(n = 102)
Between- 
group 
P value
Mean (sD) 
age, years
63.4 (11.3) 64.8 (10.8) 0.813
sex, n (%) 0.123
  Male 45 (44.1%) 57 (55.9%)
  Female 57 (55.9%) 45 (44.1%)
race/ethnicity, 
n (%)
0.477
  Black 26 (25.5%) 24 (23.5%)
  White 57 (55.9%) 63 (61.8%)
  hispanic 17 (16.7%) 15 (14.7%)
  Asian 1 (1.0%) 0 (0.0%)
  Other 1 (1.0%) 0 (0.0%)
Abbreviation: sD, standard deviation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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for early discontinuation of patients from the study were 
adverse events (n = 5) and subject withdrawal (n = 2) in 
the fixed-combination plus latanoprost group and adverse 
events (n = 4) and noncompliance (n = 2) in the timolol plus 
latanoprost group. The per protocol patient population used 
for efficacy analyses represented 95.6% (195/204) of all 
randomized patients.
IOP-lowering efficacy
The mean IOP in each treatment group at each time point 
in the study is listed in Table 2. There were no statistically 
significant differences between groups at the baseline visit 
on latanoprost (P $ 0.229). At week 12, mean IOP was 
reduced at each time point in both treatment groups after 
the addition of adjunctive study medication (P # 0.001). 
In the primary study endpoint, at 10 am, week 12, the 
mean (± standard deviation) IOP was 15.1 ± 2.6 mmHg 
in the eyes treated with fixed brimonidine-timolol and 
16.9 ± 2.5 mmHg in the timolol-treated eyes (P , 0.001). 
The mean change from latanoprost-treated baseline IOP 
at 10 am, week 12, was 8.3 ± 3.4 mmHg (35.5%) in the 
fixed combination plus latanoprost group compared with 
6.2 ± 2.8 mmHg (27.0%) in the timolol plus latanoprost 
group (P , 0.001, Figure 2). Adjunctive brimonidine-
timolol also provided significantly greater IOP lower-
ing than adjunctive timolol at the 10 am (peak effect) 
measurement at week 6 (between-group   difference of 
Run-in on latanoprost
Washout of any other
medications 
Screening
day -28 to -2
Baseline
day 0
Follow-up
week 6
Follow-up
week 12 
(exit)
Baseline on latanoprost
(after ≥ 4 weeks monotherapy)
Randomization to adjunctive treatment
Brimonidine-timolol +
latanoprost (n = 102) 
Timolol + latanoprost
(n = 102) 
Study Visits Evaluations
Completed (n = 100)
Discontinued (n = 2)
Completed (n = 99)
Discontinued (n = 3)
Completed (n = 96)
Discontinued (n = 3)
Completed (n = 95)
Discontinued (n = 5)
Demographics, medical history,
subject eligibility, prior and 
concomitant medication/
procedures, IOP, biomicroscopy,
ophthalmoscopy, visual acuity,
visual fields
Subject eligibility, prior and
concomitant medication/procedures,
IOP (8 am, 10 am), adverse events, 
biomicroscopy, visual acuity, 
urine pregnancy test (women with potential 
for pregnancy only)
Prior and concomitant
medication/procedures, 
IOP (8 am, 10 am), adverse events,
 biomicroscopy, visual acuity 
Prior and concomitant
medication/procedures, 
IOP (8 am, 10 am), 
adverse events, biomicroscopy,
ophthalmoscopy, visual acuity 
Patient recruitment
Figure 1 study design and patient flow through the study.
Abbreviation: iOP, intraocular pressure.
Table 2 Mean iOP at each time point and visit
IOP, mmHg, mean (SD) Between- 
group 
P value
Fixed brimonidine- 
timolol and 
latanoprost  
(n = 94–98)
Timolol and   
latanoprost 
(n = 94–97)
Baseline on latanoprost
  8 am 23.7 (2.2) 23.5 (2.4) 0.534
  10 am 23.4 (2.3) 23.0 (1.8) 0.229
Week 6
  8 am 17.3 (2.9) 17.8 (3.2) 0.178
  10 am 15.9 (3.1) 16.7 (2.8) 0.021
Week 12
  8 am 17.0 (2.6) 17.7 (2.6) 0.069
  10 am 15.1 (2.6) 16.9 (2.5) ,0.001
Abbreviations: sD, standard deviation; iOP, intraocular pressure.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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0.9 mmHg, P = 0.021, Figure 2). At the 8 am (trough 
effect)   measurements, the mean reduction from baseline 
IOP on latanoprost was up to 6.7 mmHg with adjunctive 
brimonidine-timolol and up to 5.9 mmHg with adjunctive 
timolol; the between-group differences were not statisti-
cally significant (Figure 2).
Response rates were higher with adjunctive brimonidine-
timolol (Table 3). A significantly higher percentage of 
patients in the brimonidine-timolol plus latanoprost group 
than in the timolol plus latanoprost group achieved at least a 
20%, 25%, 30%, and 35% reduction in IOP from the latano-
prost baseline at both the 8 am and 10 am time points at week 
12 (P # 0.047). Further, at week 12, patients treated with 
fixed brimonidine-timolol plus latanoprost were significantly 
more likely than patients treated with timolol plus latanoprost 
to achieve IOP ,18 mmHg, ,17 mmHg, and ,16 mmHg 
consistently at both 8 am and 10 am (Figure 3). The percent-
age of patients with IOP less than 18 mmHg at both peak and 
trough measurements was 59.6% in the brimonidine-timolol 
plus latanoprost group versus 42.6% in the timolol plus 
latanoprost group (P = 0.028).
Safety and tolerability
Both adjunctive study treatments were well tolerated and 
associated with a low incidence of adverse events (Table 4). 
Adverse events were reported for 15 patients (14.7%) in the 
adjunctive fixed brimonidine-timolol group and 13 patients 
(12.7%) in the adjunctive timolol group (P = 0.839). There 
was no statistically significant difference between treatment 
groups in the overall incidence of adverse events or in the 
incidence of ocular or treatment-related adverse events. 
P = 0.178
P = 0.021
P = 0.069
P < 0.001
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Figure 2 Mean change from latanoprost-treated baseline intraocular pressure at each time point after addition of fixed-combination brimonidine or timolol. Error bars, 
standard error of the mean.
Abbreviation: iOP, intraocular pressure.
Table 3 Percentage of patients with at least a 20%, 25%, 30%, or 
35% reduction in IOP from latanoprost baseline at both the 8 am 
and 10 am time points at week 12
Patients, n (%) Between- 
group 
P value
Fixed 
brimonidine-timolol 
and latanoprost 
(n = 94)
Timolol and 
latanoprost 
(n = 94)
$20% reduction 
in IOP from 
latanoprost 
baseline
68 (72.3%) 54 (57.5%) 0.047
$25% reduction 
in IOP from 
latanoprost 
baseline
55 (58.5%) 40 (42.6%) 0.041
$30% reduction 
in IOP from 
latanoprost 
baseline
44 (46.8%) 21 (22.3%) ,0.001
$35% reduction 
in IOP from 
latanoprost 
baseline
23 (24.5%) 8 (8.5%) 0.005Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Five patients treated with fixed brimonidine-timolol plus 
latanoprost discontinued from the study due to adverse 
events (one contact dermatitis/itching/redness, one allergic 
conjunctivitis, one allergic conjunctivitis/contact dermati-
tis, one itching/crusting/redness/swelling, and one allergy 
to study medication), and four patients in the timolol plus 
latanoprost group withdrew from the study due to adverse 
events (one severe punctate keratitis, one discomfort/
swelling/redness, one exacerbation of chronic obstruc-
tive pulmonary disease/bronchitis/hypertension, and one 
progression of diabetic retinopathy). The treatment-related 
adverse events that occurred during the study are listed 
in Table 5. The most common treatment-related adverse 
events were ocular allergy in the fixed brimonidine-timolol 
plus latanoprost group (four patients, 3.9%) and punc-
tate keratitis in the timolol plus latanoprost group (three 
patients, 2.9%). There were no reports of dry mouth. Only 
one patient had a serious adverse event. This patient was in 
the timolol plus latanoprost group and had acute exacerba-
tion of chronic obstructive pulmonary disease and serious 
bacterial bronchitis.
Findings on biomicroscopy following 12 weeks of treat-
ment were similar in the treatment groups. Increases in the 
severity of findings (lids/lashes, conjunctiva, cornea, anterior 
chamber, and lens) from the latanoprost-treated baseline 
were rare in both treatment groups. Conjunctival hyperemia 
and conjunctival follicles were the most common findings, 
with 5% of patients in the timolol plus latanoprost group 
demonstrating at least a one grade increase in conjunctival 
3.2%
12.8%
26.6%
46.8%
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Figure 3 Percentage of patients achieving specified intraocular pressure levels at both the 8 am and 10 am measurements at week 12.
Abbreviation: iOP, intraocular pressure.
Table 4 Summary of adverse events
Incidence, n (%) Between- 
group 
P value
Fixed 
brimonidine-timolol  
and latanoprost 
(n = 102)
Timolol and 
latanoprost  
(n = 102)
Any adverse 
event
15 (14.7%) 13 (12.7%) 0.839
Treatment- 
related adverse 
event
10 (9.8%) 4 (3.9%) 0.164
Ocular adverse 
event
9 (8.8%) 7 (6.9%) 0.796
Treatment- 
related  
ocular adverse 
event
8 (7.8%) 4 (3.9%) 0.373
serious adverse  
event
0 (0.0%) 1 (1.0%)a .0.999
Notes: aAcute exacerbation of chronic obstructive pulmonary disease and bacterial 
bronchitis.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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hyperemia, and 2% of patients in the brimonidine-timolol 
plus latanoprost group demonstrating at least a one grade 
increase in conjunctival follicles (Figure 4).
Discussion
Achieving and maintaining a low target IOP minimizes 
the risk of glaucomatous progression and vision loss.11,12 
Prostaglandin analogs are commonly used as first-line therapy 
in glaucoma and ocular hypertension because they reduce 
IOP effectively, have a favorable safety profile, and are 
conveniently dosed just once daily. However, many patients 
treated initially with a prostaglandin analog subsequently 
require adjunctive therapy to reach their target pressure.2 In 
the present study, both fixed brimonidine-timolol and timolol 
alone reduced IOP from the latanoprost baseline. However, 
use of fixed-combination brimonidine-timolol as adjunctive 
therapy to latanoprost provided significantly greater IOP 
lowering compared with adjunctive timolol and was well 
tolerated, with few discontinuations due to adverse events.
At 12 weeks, adjunctive fixed brimonidine-timolol pro-
vided an 8.3 mmHg (35.5%) reduction in IOP from latanoprost 
baseline at peak effect, approximately 2 mmHg larger than 
the 6.2 mmHg (27.0%) reduction from latanoprost baseline 
provided by adjunctive timolol (P , 0.001). These results are 
consistent with those of a previous randomized controlled 
study that compared fixed brimonidine-timolol with fixed 
dorzolamide-timolol as therapy adjunctive to a   prostaglandin 
analog.10 In that study, the mean additional reduction from 
the prostaglandin analog-treated baseline IOP was 6.9 mmHg 
(29.3%) in the 37 patients who added fixed brimonidine-
timolol to a prostaglandin analog and 5.2 mmHg (23.5%) 
in the 42 patients who added fixed dorzolamide-timolol to a 
prostaglandin analog.10
The efficacy of timolol as an agent adjunctive to latano-
prost has been inconsistent in previous studies.13–16 In an early 
controlled randomized study evaluating the effectiveness of 
timolol given once daily in the morning as therapy adjunc-
tive to latanoprost, adjunctive timolol reduced IOP from the 
latanoprost-treated baseline by approximately 4 mmHg at 
peak effect and 3 mmHg at trough effect.13
More recent studies comparing the fixed combination of 
timolol and latanoprost with latanoprost monotherapy have 
shown that the fixed combination provides approximately 
1–2 mmHg additional IOP lowering compared with latano-
prost alone.14–16 Randomized, controlled studies have also 
shown that brimonidine effectively reduces IOP when added 
to a prostaglandin analog.17,18 Three times daily brimonidine 
purite 0.1% provided additional IOP lowering of 4.8 mmHg 
at peak effect and 2.2 mmHg at trough effect when used as 
adjunctive therapy to latanoprost.17
The addition of fixed brimonidine-timolol to latanoprost 
in this study was as well tolerated as the addition of timolol 
alone. There were few adverse events in either treatment 
group, and the rate of discontinuations due to adverse events 
was comparable in the two treatment groups. For patients 
treated with adjunctive fixed brimonidine-timolol in this 
study, the overall incidence of treatment-related adverse events 
was 9.8%, approximately half the 20.2% overall incidence 
of treatment-related adverse events reported by Gõni4 in a 
previous 12-week, randomized controlled study that evaluated 
fixed brimonidine-timolol used alone in 188 patients with 
glaucoma or ocular hypertension. These results suggest that 
fixed brimonidine-timolol may be particularly well tolerated 
when used adjunctively to a prostaglandin analog.
Fixed combinations offer advantages of improved con-
venience and typically lower cost compared with separate 
use of the component medications. The addition of a fixed 
combination to a prostaglandin analog provides substantial 
additional IOP lowering while adding only one bottle to 
the patients’ daily regimen. Because use of more than two 
bottles of IOP-lowering medication may be associated with 
an increase in noncompliance, minimization of the number 
of bottles and drops used by patients is desirable to facilitate 
adherence with treatment and improve visual outcomes.
Table 5 Treatment-related adverse events
Events (n)a
Fixed 
brimonidine-timolol  
and latanoprost 
(n = 102)
Timolol and 
latanoprost  
(n = 102)
Superficial punctate  
keratitis
1 3
itching 3 0
redness 2 1
Allergic conjunctivitis 2 0
Contact dermatitis 2 0
eye swelling 1 1
Allergy to study  
medication
1 0
Crusting 1 0
Discomfort 0 1
Dizziness/lightheadedness 1 0
Drowsiness 1 0
Fatigue 1 0
high intraocular pressure 1 0
Low heart rate 1 0
Ocular burning 0 1
Notes: aMultiple  treatment-related  adverse  events  were  reported  in  individual 
patients.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
952
Fechtner et al
The primary limitation of this study was that the 
duration of treatment was only three months and IOP was 
measured at only two time points at each visit. Ocular 
allergy, a known side effect of brimonidine treatment, 
typically is a delayed response that presents after more 
than three months of therapy.3,19,20 In addition, the inclu-
sion criteria specified that all patients required an IOP of 
at least 21 mmHg after at least four weeks of latanoprost 
therapy, and patients who were nonresponders to latano-
prost were not specifically excluded. This may partially 
explain the greater IOP lowering for timolol than has 
been seen in previous trials.13–16 Further studies will be 
needed to determine the safety and efficacy of fixed 
brimonidine-timolol added to a prostaglandin analog 
over long-term treatment, as well as the effectiveness of 
adjunctive brimonidine-timolol in providing additional 
IOP lowering over 24 hours.
In summary, this study demonstrated that fixed-
  combination brimonidine-timolol reduces IOP signifi-
cantly more effectively than timolol when used as therapy 
adjunctive to latanoprost. Adjunctive treatment with fixed 
brimonidine-timolol was also well tolerated. Given potential 
medication compliance issues, a regimen of a prostaglandin 
analog and the fixed combination of brimonidine and timolol, 
which requires instillation of just three drops in the eye 
each day, may represent optimal maximal medical therapy 
for many patients.
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Biomicroscopy findings
Fixed brimonidine−timolol + latanoprost (n = 98)
Timolol + latanoprost (n = 96)
Figure 4 Percentage of patients with at least a one grade increase from latanoprost-treated baseline in severity scores on biomicroscopy at week 12.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
953
Brimonidine-timolol versus timolol added to latanoprost
support from Allergan Inc. JW and DAH are employees of 
Allergan Inc.
References
  1.  Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular   Hypertension 
Treatment Study: a randomized trial determines that topical ocular 
hypotensive medication delays or prevents the onset of primary open-
angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.
  2.  Covert D, Robin AL. Adjunctive glaucoma therapy use associated 
with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 
2006;22(5):971–976.
  3.  Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% 
brimonidine−0.5% timolol fixed-combination therapy vs mono-
therapy with timolol or brimonidine in patients with glaucoma or 
ocular hypertension: A 12-month randomized trial. Arch Ophthalmol. 
2006;124(9):1230–1238.
  4.  Goñi FJ; Brimonidine/Timolol Fixed Combination Study Group. 
12-week study comparing the fixed combination of brimonidine 
and timolol with concomitant use of the individual components in 
patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 
2005;15(5):581–590.
  5.  Fechtner RD, Realini T. Fixed combinations of topical glaucoma 
medications. Curr Opin Ophthalmol. 2004;15(2):132–135.
  6.  Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence 
to the initial primary therapy? Ophthalmology. 2005;112(5):863–868.
  7.  Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition 
of a third or fourth antiglaucoma medication effective? J Glaucoma. 
2004;13(2):130–136.
  8.  Crichton ACS. Timolol/brimonidine combination therapy in glaucoma 
management. Clin Surg J Ophthalmol. 2005;23:356–359.
  9.  Ahmed I. CEED II: An in-depth look at the latest findings. Clin Surg 
J Ophthalmol. 2007;25:1–5.
  10.  Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S,   Hollander 
DA. Three-month, randomized, parallel-group comparison of brimo-
nidine-timolol versus dorzolamide-timolol fixed-combination therapy. 
Curr Med Res Opin. 2009;25(7):1645–1653.
  11.  The AGIS Investigators. The Advanced Glaucoma Intervention Study 
(AGIS): 7. The relationship between control of intraocular pressure and 
visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440.
  12.  Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; 
Early Manifest Glaucoma Trial Group. Factors for glaucoma progres-
sion and the effect of treatment: The Early Manifest Glaucoma Trial. 
Arch Ophthalmol. 2003;121(1):48–56.
  13.  Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. 
Efficacy and safety of timolol solution once daily vs timolol gel added 
to latanoprost. Am J Ophthalmol. 1999;128(6):692–696.
  14.  Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combi-
nation Investigative Group. Latanoprost and timolol combination 
therapy vs monotherapy: One-year randomized trial. Arch Ophthalmol. 
2002;120(7):915–922.
  15.  Pfeiffer N; European Latanoprost Fixed Combination Study Group. 
A comparison of the fixed combination of latanoprost and timolol 
with its individual components. Graefes Arch Clin Exp Ophthalmol. 
2002;240(11):893–899.
  16.  Olander K, Zimmerman TJ, Downes N, Schoenfelder J;   Xalacom/ 
Latanoprost  Study  Group.  Switching  from  latanoprost  to 
  fixed-combination latanoprost-timolol: A 21-day, randomized, double-
masked, active-control study in patients with glaucoma and ocular 
hypertension. Clin Ther. 2004;26(10):1619–1629.
  17. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzo-
lamide 1% as adjunctive therapy to latanoprost in patients with 
glaucoma or ocular hypertension. Curr Med Res Opin. 2008;24(5): 
1435–1442.
  18.  Feldman RM, Tanna AP, Gross RL, et al; Additivity Study Group. 
Comparison of the ocular hypotensive efficacy of adjunctive brimoni-
dine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. 
Ophthalmology. 2007;114(7):1248–1254.
  19.  Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine 
allergy in patients previously allergic to apraclonidine. J Glaucoma. 
2000;9(3):235–238.
  20.  Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, 
  Schiffman R; Combigan Study Group. Brimonidine and timolol fixed-
combination therapy versus monotherapy: A 3-month randomized trial 
in patients with glaucoma or ocular hypertension. J Ocul Pharmacol 
Ther. 2005;21(4):337–348.